FreeStyle Libre 2 System is proven to Improve Glucose Control

Increased time in target range

Increased monitoring with FreeStyle Libre 2 system was associated with 43% more time in range*1

Reduced time in hypoglycemia

Increased monitoring with FreeStyle Libre 2 system was associated with 40% less time in hypoglycemia*2

Reduced A1c

Real-world study showed a 0.9% reduction of A1c in patients with T2D,*†3 while a meta-analysis across patients with T1D and T2D showed a 0.55% reduction4

Reduced hospital admission

Diabetes-related hospital admission rates decreased from 13.7% to 4.7% over 12 months (P<0.05)5

Understanding of glucose variability

95% of users reported having a better understanding of their glucose fluctuations with the FreeStyle Libre 2 system5

Increased monitoring frequency

FreeStyle Libre 2 users test glucose 12 times on average per day*1

Reveal A More Complete Glucose Picture

Recommendations based on patient type endorsed by the American Diabetes Association and the leading diabetes professional associations state that time in range6:

  • Provides more actionable information than A1c alone
  • Ambulatory Glucose Profile should complement A1c for a wide range of patients with diabetes

Significantly Increased Time In Range

FreeStyle Libre 2 system is clinically proven to increase time spent in target range*

More time in range*1

(70-180 mg/dL)

P<0.001 (38.5 scans/day vs 3.5 scans/day)

Less time in hypoglycemia*2

(<55 mg/dL)

P<0.001 (48.1 scans/day vs 4.4 scans/day)

Clinically Proven to Improve Glucose Control for Both T1D and T2D Patients

In a real-world study of patients with T2D on insulin, FreeStyle Libre 2 system users saw significantly reduced A1c levels*3

Average A1c reduction*3

18 Medical Centers • 363 patients
A1c reduction was seen in 3 to 6 months.

In a meta-analysis, FreeStyle Libre 2 system significantly reduced A1c in patients with T1D and T2D*‡4

Average A1c reduction*4

No significant differences were seen based on study length, type of diabetes, or age.

The higher the initial A1c, the greater the A1c reduction.*§7

*Data from this study was collected with the outside US version of FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional, real-time glucose alarms. Therefore, the study data is applicable to both products.

Based on a real-world study of 363 patients with T2D on insulin that took place across 18 medical centers.

A meta-analysis of clinical and real-world observational studies amongst patients with type 1 or type 2 diabetes, including children and adults was conducted to assess impact of using FreeStyle Libre 14 day system on A1c.

§Based on regression analysis, the degree of change in HbA1c correlates with the initial HbA1c. For each percentage point above 7.0%, an additional 0.4% reduction is expected with FreeStyle Libre 14 day system.

References: 1. Lang J, Jangam SR, Dunn TC, Hayter G. Expanded real-world use confirms strong association between frequency of flash glucose monitoring and glucose control. Presented at: 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019); February 20-23, 2019; Berlin, Germany. 2. Dunn TC, Xu Y, Hayter G, Ajjan RA. Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: a European analysis of over 60 million glucose tests. Diabetes Res Clin Pract. 2018;137:37-46. 3. Kroeger J, Fasching P, Hanaire H. Meta-analysis of three, real-world, chart review studies to determine the effectiveness of Freestyle Libre flash glucose monitoring system on HbA1c in adults with type 2 diabetes. Poster presented at: 79th Scientific Sessions of the American Diabetes Association; June 7-11, 2019; San Francisco, CA. 4. Evans M, Welsh Z, Ells S, Seibold A. The impact of flash glucose monitoring on glycaemic control as measured by HbA1c: a meta-analyis of clinical trials and real-world observational studies. Diabetes Ther. 2020;11(1):83-95. 5. Fokkert M, van Dijk P, Edens M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diab Res Care. 2019;7(1):e000809. doi:10.1136/bmjdrc-2019-000809. 6. Battelino T, Danne T, Berganstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593-1603. 7. Data on file. Abbott Diabetes Care.

ADC-09305 v4.0 07/20